Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial
Open accessPublished version of a preprint
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To directly compare the efficacy and safety of a fixed-ratio combination, of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi), with those of a premix insulin analog, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspart protamine) (BIAsp 30) as treatment advancement in type 2 diabetes suboptimally controlled on basal insulin plus oral antihyperglycemic drugs (OADs). RESEARCH DESIGN AND METHODS: In SoliMix, a 26-week, open-label, multicenter study, adults with suboptimally controlled basal insulin–treated type 2 diabetes (HbA1c ≥7.5% and ≤10%) were randomized to once-daily iGlarLixi or twice-daily BIAsp 30. Primary efficacy end points were noninferiority in HbA1c reduction (margin 0.3%) or superiority in body weight change for iGlarLixi versus BIAsp 30. RESULTS: Both primary efficacy end points were met: after 26 weeks, baseline HbA1c (8.6%) was reduced by 1.3% with iGlarLixi and 1.1% with BIAsp 30, meeting noninferiority (least squares [LS] mean difference −0.2% [97.5% CI −0.4, −0.1]; P < 0.001). iGlarLixi was also superior to BIAsp 30 for body weight change (LS mean difference −1.9 kg [95% CI −2.3, −1.4]) and percentage of participants achieving HbA1c <7% without weight gain and HbA1c <7% without weight gain and without hypoglycemia (all P < 0.001). iGlarLixi was also superior versus BIAsp 30 for HbA1c reduction (P < 0.001). Incidence and rates of American Diabetes Association level 1 and 2 hypoglycemia were lower with iGlarLixi versus BIAsp 30. CONCLUSIONS: Once-daily iGlarLixi provided better glycemic control with weight benefit and less hypoglycemia than twice-daily premix BIAsp 30. iGlarLixi is a more efficacious, simpler, and well-tolerated alternative to premix BIAsp 30 in suboptimally controlled type 2 diabetes requiring treatment beyond basal insulin plus OAD therapy. Video 1:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pharmacokinetic and pharmacodynamic studies of combination GLP-1 RAs and basal insulin analogs have shown an additive effect on BG decreases.1021,1094–1097”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1094]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455 · cited 2×
“With this approach, advancing basal insulin therapy involves four options: 1) adding rapid-acting insulin progressively to an existing basal insulin regimen; 2) multiple daily premix insulin doses (basal and prandial insulin co-formulation); 3) adding a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 R…”
BackgroundMethod9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 2×
“Each aforementioned treatment option has been shown to improve glycemic control when used to advance therapy from basal insulin but are also associated with specific adverse effects (4-7).”
BackgroundGough, S. C. L., Bode, B., Woo, V., Rodbard, H. W., Linjawi, S., Poulsen, P., Damgaard, L. H., & Buse, J. B. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70174-3 · Cited by 366
Rosenstock, J., Aronson, R., Grunberger, G., Hanefeld, M., Piatti, P., Serusclat, P., Cheng, X., Zhou, T., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0917 · Cited by 272 · cited 3×
“Both have been shown to provide improved glycemic control versus their individual components, along with weight-benefits compared with basal insulin and fewer gastrointestinal AEs compared with their GLP-1 RA component (17-22).”
BackgroundResultSelf-citationAroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1495 · Cited by 260
Self-citationBuse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014) · Diabetes Care · doi:10.2337/dc14-0785 · Cited by 259 · cited 2×
“Both have been shown to provide improved glycemic control versus their individual components, along with weight-benefits compared with basal insulin and fewer gastrointestinal AEs compared with their GLP-1 RA component (17-22).”
BackgroundLingvay, I., Manghi, F. P., García-Hernández, P., Norwood, P., Lehmann, L., Tarp-Johansen, M. J., Buse, J. B., & for the DUAL V Investigators (2016) · JAMA · doi:10.1001/jama.2016.1252 · Cited by 220 · cited 1×
“4%) (17-22; 28), lower than previously observed in participants initiating GLP-1 RAs alone (18; 20), and very rarely led to treatment discontinuation (0.”
BackgroundVijan, S., Hayward, R. A., Ronis, D. L., & Hofer, T. P. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0117.x · Cited by 202 · cited 2×
“Each aforementioned treatment option has been shown to improve glycemic control when used to advance therapy from basal insulin but are also associated with specific adverse effects (4-7).”
BackgroundLiebl, A., Prager, R., Binz, K., Kaiser, M., Bergenstal, R., Gallwitz, B., & PREFER Study Group (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00915.x · Cited by 149 · cited 1×
“Similarly, the glycemic control and bodyweight changes observed for premix BIAsp 30 in the present study are consistent with previous RCTs of premix BIAsp 30 in adults with type 2 diabetes advancing basal insulin therapy (25-27).”
ResultJi, L.-N., Lu, J.-M., Guo, X.-H., Yang, W.-Y., Weng, J.-P., Jia, W.-P., Zou, D.-J., Zhou, Z.-G., Yu, D.-M., Liu, J., et al. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-602 · Cited by 142 · cited 1×
“Despite this, premix insulins are widely used globally, particularly in Asia, Africa, the Middle East, China and some EU countries (8-11).”
BackgroundLinjawi, S., Bode, B. W., Chaykin, L. B., Courrèges, J.-P., Handelsman, Y., Lehmann, L. M., Mishra, A., & Simpson, R. W. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0218-3 · Cited by 136 · cited 5×
“Full baseline characteristics have been reported previously (22).”
BackgroundInfluentialAschner, P., Gagliardino, J. J., Ilkova, H., Lavalle, F., Ramachandran, A., Mbanya, J. C., Shestakova, M., Chantelot, J.-M., & Chan, J. C. N. (2020) · Diabetologia · doi:10.1007/s00125-019-05078-3 · Cited by 120 · cited 1×
“Despite this, premix insulins are widely used globally, particularly in Asia, Africa, the Middle East, China and some EU countries (8-11).”
BackgroundGlucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107 · cited 1×
“GLP-1 RA therapy can be associated with gastrointestinal (GI) adverse events (AEs) and resultant adherence issues (4).”
BackgroundBlonde, L., Rosenstock, J., Del Prato, S., Henry, R., Shehadeh, N., Frias, J., Niemoeller, E., Souhami, E., Ji, C., & Aroda, V. R. (2019) · Diabetes Care · doi:10.2337/dc19-1357 · Cited by 85 · cited 3×
“Both have been shown to provide improved glycemic control versus their individual components, along with weight-benefits compared with basal insulin and fewer gastrointestinal AEs compared with their GLP-1 RA component (17-22).”
BackgroundResultSelf-citationBasal Insulin Intensification in Patients with Type 2 Diabetes: A Review
Meece, J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0395-3 · Cited by 51 · cited 2×
“Each aforementioned treatment option has been shown to improve glycemic control when used to advance therapy from basal insulin but are also associated with specific adverse effects (4-7).”
BackgroundPolinski, J. M., Kim, S. C., Jiang, D., Hassoun, A. A. K., Shrank, W. H., Cos, X., Rodríguez-Vigil, E., Suzuki, S., Matsuba, I., Seeger, J. D., et al. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0044-z · Cited by 48 · cited 1×
“Despite this, premix insulins are widely used globally, particularly in Asia, Africa, the Middle East, China and some EU countries (8-11).”
BackgroundLaSalle, J. R., & Berria, R. (2013) · PubMed · Cited by 38
Blonde, L., Anderson, J. E., Chava, P., & Dendy, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541790 · Cited by 33 · cited 11×
“Continuous secondary efficacy end points (e.g., FPG and total daily insulin dose) were analyzed using the same approach as the primary end points including the baseline values for the end point in question as fixed covariates.”
BackgroundInfluentialMcCrimmon, R. J., Sifri, S. A., Emral, R., Mohan, V., Sauque‐Reyna, L., Trescolí, C., Lalic, N. M., Alvarez, A., Demil, N., Coudert, M., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14354 · Cited by 31 · cited 1×
“Detailed methods have been previously published (23).”
Self-citationLigthelm, R. J., Gylvin, T., DeLuzio, T., & Raskin, P. (2010) · Endocrine Practice · doi:10.4158/ep10079.or · Cited by 25 · cited 4×
“However, incidence of hypoglycemia in previous RCTs was generally higher for both treatments (40% for iGlarLixi and ~70% for premix BIAsp 30) than that observed in the present study (17; 26; 27), possibly due to the absence of sulfonylurea use in this study.”
BackgroundResultInfluentialJin, S., Kim, J. H., Min, K. W., Lee, J. H., Ahn, K. J., Park, J. H., Jang, H. C., Park, S. W., Lee, K. W., Won, K. C., et al. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12312 · Cited by 23 · cited 2×
“However, incidence of hypoglycemia in previous RCTs was generally higher for both treatments (40% for iGlarLixi and 70% for premix BIAsp 30) than that observed in the current study (17,26,27), possibly due to the absence of sulfonylurea use in this study.”
ResultHome, P. D., Blonde, L., Kalra, S., Ji, L., Guyot, P., Brulle-Wohlhueter, C., Murray, E. M., Shah, R., Sayre, T., & Shaunik, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14148 · Cited by 22 · cited 1×
“(24) comparing iGlarLixi versus basalbolus or premix insulins.”
BackgroundTibaldi, J. M. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.019 · Cited by 11 · cited 1×
“However, hypoglycemia rates have been shown to be higher with other premix insulin regimens than with premix insulin 30/70 (30), so the benefits of iGlarLixi over other premix insulins could be even greater.”
Background
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Jude, E. B., Malecki, M. T., Gomez Huelgas, R., Prazny, M., Snoek, F., Tankova, T., Giugliano, D., & Khunti, K. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01222-2 · Cited by 52
“They also involve a single daily injection, contributing to regimen simplification and a reduction of treatment burden [51, 63].”
BackgroundBala, C. G., Cerghizan, A., Mihai, B. M., Moise, M., & Guja, C. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060852 · Cited by 26
Polonsky, W. H., Giorgino, F., Rosenstock, J., Whitmire, K., Lew, E., Coudert, M., Alvarez, A., Nicholls, C. J., & McCrimmon, R. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14822 · Cited by 22
“The SoliMix trial was the first randomized head-to-head study to directly compare the efficacy and safety of iGlarLixi with premix insulin BIAsp 30 in adults with suboptimally controlled T2D on basal insulin plus one or two OADs.10 SoliMix showed that iGlarLixi versus BIAsp 30 was associated with greater HbA1c reducti…”
BackgroundMethodResultInfluentialSelf-citationLiu, M. R., Gu, W., Chen, L., Li, Y., Kuang, H., Du, J., Alvarez, A., Lauand, F., Souhami, E., Zhang, J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15724 · Cited by 22
Self-citation
Metadata
- Authors
- Rosenstock, J., Emral, R., Sauque-Reyna, L., Mohan, V., Trescolí, C., Al Sifri, S., Lalic, N., Alvarez, A., Picard, P., Bonnemaire, M., Demil, N., & McCrimmon, R. J.
- Affiliations
- Dallas Diabetes Research Center (US)
- Department of Endocrinology and Metabolic Diseases, Ankara University Faculty of Medicine, Ankara, Turkey
- Instituto de Diabetes Obesidad y Nutrición S.C., Cuernavaca, Morelos, Mexico
- Madras Diabetes Research Foundation (IN)
- Hospital de La Ribera (ES)
- Al Hada Military Hospital, Taif, Saudi Arabia
- University of Belgrade (RS)
- Sanofi (Argentina) (AR)
- IviData LIFE SCIENCES, Levallois-Perret, France
- Sanofi (France) (FR)
- University of Dundee (GB)
- Corresponding author
- Rosenstock, Julio
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-08-06
- Volume
- 44
- Issue
- 10
- Pages
- 2361-2370
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC8740944
- OpenAlex
- W3176298177
- Cited by
- 63
- References
- 27
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 16 · 2023: 12 · 2022: 12
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, basal insulin, iGlarLixi, lixisenatide, insulin glargine, biphasic insulin aspart, premixed insulin, GLP-1 receptor agonists, glycemic control, HbA1c reduction, weight change, hypoglycemia, suboptimal glycemic control, oral antidiabetic drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.